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axial involvement the reduction of BASDAI and
BASFI was not statistically significative. On top of
that, PASI score suffered a reduction of 64%. Four-
teen patients (33.3%) had to switch their TNF an-
tagonist treatment. 58.8% of the switches were due
to adverse effects and 41.2% due to therapy failure.
Regarding the 56 adverse reactions registered, only
one was a severe reaction. The remaining adverse
reactions were not severe and 67% of them were
due to infections. 
Discussion:The results of this first report of the use
of the BioRePortAP in clinical practice confirm the
efficacy and safety of TNF antagonist treatment in
PsA. The results shown here elucidate the potential
applications of BioRePortAP as a tool for efficacy
and safety assessment of PsA patients treated with
biotechnological drugs. 
Keywords: Psoriatic Arthritis; Registry; BioRepor-
tAP; Biological Therapy; Portugal.
Introduction
Psoriatic arthritis (PsA) has been defined as an in-
flammatory arthritis associated with psoriasis and
seronegative for rheumatoid factor. PsA affects men
and women almost equally. The average age at on-
set in most studies is 36-40 years. The classic des-
cription of PsA includes five clinical patterns1. The-
se patterns include distal interphalangeal (DIP)
joint involvement, oligoarticular pattern (<5 joints
involved) which is usually asymmetric in distribu-
tion, a polyarticular pattern (>5 joints involved),
which is symmetric in only half the patients, arthri-
tis mutilans, which is a very destructive form of
arthritis and spondyloarthritis, affecting the sacroi-
liac joints and the apophyseal joints of the spine,
with a clinical pattern often similar to ankylosing
spondylitis (AS)2.
Over the past few years, there has been a rene-
Abstract
Aims:To evaluate the efficacy and safety of the tre-
atment of psoriatic arthritis (PsA) patients with tu-
mor necrosis factor (TNF) antagonists in the Rheu-
matology Department of Hospital de Santa Maria
using the BioRePortAP. 
Methods:The Portuguese Society of Rheumatology
(SPR) developed an electronic medical chart cou-
pled with a database for the follow up of PsA pati-
ents, the BioRePortAP, which was launched in May
2009. This evaluation was based on all the PsA pa-
tients that were on active treatment with TNF an-
tagonists in September 2009 and were registered in
the BioRePortAP. All the previous data on these pa-
tients were introduced in BioRePortAP using the
prospective paper based follow up protocol that
this Department was using since 1999. Only pa-
tients with more than 9 months of treatment were
analyzed. 
Results:Forty-two patients with PsA, actively trea-
ted with anti-TNF agents in September 2009, for at
least 9 months, were analyzed in BioRePortAP.
Twenty-three patients were male (55%) and nine-
teen were female (45%). The average age of these
patients was 49.8±10.9 years old, the average disea-
se duration was of 10.7±5.6 years and the mean du-
ration of biological therapy was of 37.8±27.8
months. For the 81% of patients with peripheral jo-
int disease there was a mean reduction of more
than 80% in the swollen and tender joint counts,
and almost 50% in the health assessment question-
naire (HAQ) value. In the 19% of the patients with
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wed interest in the treatment of PsA. This has resul-
ted from the advent of tumor necrosis factor (TNF)
antagonist therapy that had proven to be highly ef-
fective in both psoriasis and PsA3. TNF is a leading
cytokine for the inflammatory aspects noted in the
skin and joints and it is a key upstream factor in the
activation of other chemokines and cytokines,
which may lead to cartilage and bone destruction
and to skin scarring. Thus, it is not surprising that
tackling TNF leads to marked improvement in joint
and skin symptoms and prevents joint destruction
and permanent skin lesions. At this moment, only
3 anti TNF treatments are reimbursed in Portugal
for the treatment of adult patients with active PsA
who have responded inadequately to disease-mo-
difying anti-rheumatic drugs (DMARDs): adalimu-
mab, etanercept and infliximab. Etanercept, a re-
combinant human soluble TNF receptor is a di-
meric fusion protein consisting of the extracellu-
lar portion of the human p75 TNF receptor linked
to the Fc portion of a Type 1 human immunoglo-
bulin (IgG1). The primary action of etanercept is to
bind and inactivate soluble and cell-bound TNF
and lymphotoxin alpha. In adults, it is administe-
red 25 mg twice a week or 50 mg once a week. In-
fliximab is a chimeric monoclonal antibody that
binds specifically to human TNF and is composed
of human constant and murine variable regions.
Infliximab is administered as an intravenous infu-
sion, at a dose of 5 mg/Kg, at 0, 2, and 6 weeks fol-
lowed by infusions every 8 weeks. Adalimumab is
a fully human anti-TNF IgG1 antibody, with a me-
chanism of action similar to infliximab. It is admi-
nistered as a subcutaneous injection at a dose of
40 mg every two weeks.
In order to measure disease activity, progression
and change with therapy in PsA patients, it is im-
portant to use accurate, reliable and feasible out-
come measures that can ideally be employed in
longitudinal cohorts, clinical trials and clinical
practice4,5.
Until recently, there has been a low investment
on the development of this kind of methodology
applied to PsA. With emerging therapies, the focus
on the methodology of outcome assessment has
increased to ensure that discriminative instru-
ments are used. Most tools applied to the quanti-
fication of PsA outcomes have been borrowed from
rheumatoid arthritis (RA) and ankylosing spondyli-
tis (AS) outcome studies, but some have been spe-
cifically tested in PsA3. However, the relative varia-
bility of PsA clinical manifestations still poses a
great challenge in the assessment of real life co-
horts, which were not selected through complex
inclusion and exclusion criteria, as is the case of cli-
nical trials. 
A key assessment in rheumatology clinical 
trials is the counting of the number of tender and
swollen joints in a patient. Variable numbers of
joints are counted in various systems, such as the
American College of Rheumatology (ACR) joint
count of 68 tender and 66 swollen (excluding the
hips from assessment of swelling), developed in
1949 for the evaluation of RA6. This has been fre-
quently adapted to be used for the evaluation of
PsA patients with peripheral joint involvement (wi-
thout axial skeleton involvement) – the so called
“RA like” patients. These joint counts are then com-
bined with other core measures of disease activity
(also adapted to the use in PsA), such as patient and
physician assessed global health, through the use
of a 100 mm visual analogue scale (VAS), pain (also
using a VAS) and inflammation markers (Erythro-
cyte Sedimentation Rate, ESR, and C reactive pro-
tein, CRP)7. Another classical RA activity measure-
ment, the DAS 28 (disease activity score, based on
28 swollen and tender joints, ESR and patient glo-
bal health VAS) has been also frequently used in
PsA8. 
The ASessment in Ankylosing Spondylitis
(ASAS) working group has recommended the use
of a number of outcome measures for spinal invol-
vement in AS, which includes the Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI)9, the
Bath Ankylosing Spondylitis Function Index (BAS-
FI)10 and a set of mobility measures. This measure-
ments have been used to evaluate PsA in patients
that have axial skeleton involvement – “AS like” pa-
tients. 
PsA joint disease activity is commonly not mir-
rored by skin disease. It thus seems logical to as-
sess skin disease separately. The most widely used
system is the Psoriatic Area Severity Index (PASI)11,12
and this has been introduced in the description of
PsA clinical cohorts. 
Physical function refers to the abilities or diffi-
culties in daily activities such as walking, opening
jars, playing sports, lifting heavy objects, writing
and so forth. Assessing physical function by self-
-reported questionnaire has become a favored
approach because no special equipment or testing
personnel is required. The Health Assessment
Questionnaire (HAQ)13 is a validated questionnai-
re for measuring physical function in RA. Because
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PsA may affect people in a way similar to RA it has
been considered reasonable to use such measure
in PsA. 
An important aspect of the evaluation of the re-
sults of DMARDs treatment is the repercussion on
structural joint damage. Radiologic signs of joint
damage remain the standard method in RA clini-
cal trials, despite the advent of newer modalities
such as ultrasound and magnetic resonance ima-
ging (MRI). In PsA the distribution of joint disease
is not predictable and it remains to be determined
which joints should be scored to get a sufficiently
valid measurement of joint damage. 
Simple measures of inflammation, such as the
acute phase reactants, which include ESR and CRP
are used, but are not reliably elevated in patients
with PsA, even with active inflammation. Desirable
but not essential symptom domains to measure in-
clude enthesitis, dactylitis, nails and fatigue14-16.
As has already been done for RA and AS, the Por-
tuguese Society of Rheumatology (SPR) has deve-
loped an informatics platform which combines
features of electronic clinical chart with a databa-
se for PsA patients who are being treated with bi-
otechnological drugs – BioRePortAP. This article is
the first application of the use of BioRePortAP to a
cohort of PsA patients being followed in a Portu-
guese Rheumatology Department. In addition, this
is also the first report of a Portuguese cohort of PsA
patients treated with TNF antagonists. In fact, SPR
has promoted 2 national reports on the use of bio-
technological drugs in RA17 and AS18 but there is no
report on patients with PsA. Moreover, despite the
existence of national guidelines for treatment of
RA19 and AS20 patients with biotechnological
DMARDs, SPR has not developed this instrument
for PsA, which means that the results of this paper
can be taken into account in the future elaboration
of such guidelines. BioRePortAP will be an impor-
tant tool for monitoring the efficacy and safety of
the use of TNF antagonists in PsA at a national le-
vel and this first practical application will help to
detail the mechanisms for recording and analysis
of data.
Material and methods
BioRePortAP is an electronic clinical chart that is
linked to a database, built on the Plataform.NET
(VB.NET) and the SQL DatabaseServer. The NET
Plataform (Microsoft) allows the development of
software applications for Windows, based on
VB.NET programming language to build all the
screens used. The information entered is stored in
the SQL server database management system (Mi-
crosoft).
BioRePortAP was launched on 2 May 2009 at a
national level by SPR and all PsA patients treated
with biologic therapies in the Rheumatology De-
partment of Santa Maria´s Hospital are being col-
lected prospectively from that date. In addition,
this department had also previously started (since
1999) a prospective evaluation of all rheumatic
patients treated with biotechnological drugs
structured on a paper based protocol. This proto-
col has been adapted from an initial version pre-
pared for RA patients published initially in 2001
and updated recently21. This evaluation was based
on all PsA patients that were on active treatment
with TNF antagonists in September 2009 for more
than 9 moths and were registered in the BioRePor-
tAP. The criteria for starting TNF antagonists was
based on the clinical opinion of the assisting
physician reflecting, however, the Portuguese re-
commendations for starting biotechnological
drugs in RA19 and AS20 patients were also taken into
account.  
The key variables included in the BioRePortAP
were: sex, age, birthplace, education, current em-
ployment status, prior disease, personal history,
general clinical data (type of arthritis, the onset of
symptoms and date of diagnosis, radiological
signs, HLA B27 typing, body mass index, smoking
and alcohol consumption), surgeries, prior the-
rapy (DMARD) and current therapy (name of the
drug, starting date, dose, consumption of NSAIDs
and corticosteroids) and adverse effects. Severe ad-
verse reactions were defined as the occurrence of
death, hospitalization or any event that causes per-
manent damages. The tuberculin skin test (TST),
chest x-ray results, tuberculosis risk factors and la-
tent tuberculosis treatment is also recorded. The
complete joint count is registered, as well as patient
and physician’s global health VAS, patient’s pain
VAS, HAQ and inflammation markers (ESR and
CRP). A computer assisted automatic DAS 28 cal-
culation is available (including CRP or ESR and 3
or 4 variables)7,8. For patients with axial involve-
ment BASDAI, BASFI and mobility measurements
as defined by the ASAS group are used. Psoriasis
Area and Severity Index (PASI) is the score used for
skin involvement.
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Results
Forty-two patients with PsA, who in September
2009 were under treatment with anti-TNF agents,
for at least 9 months, were registered in BioRePor-
tAP and analyzed. Twenty-three patients were male
(55%) and nineteen were female (45%). The avera-
ge age of these patients was 49.8±10.9 years old.
The youngest was 38 and the eldest was 60 years
old. The average age at diagnosis was 38.1±11.6
years old and the average disease duration at the
current evaluation was of 10.7±5.6 years. The shor-
test disease duration was of 5 years and the longest
disease duration was of 16 years. The mean disea-
se duration at the beginning of the biological treat-
ment was of 7.9±6.5 years and the mean duration
of biological therapy currently under way was of
37.8±27.8 months (minimum of 10 months and
maximum of 5 years).
For a total of 42 patients 19% had axial skeleton
involvement and 81% peripheral joint involve-
ment. HLA-B27 was registered in 24 patients and
was positive in 4 (16.7%) of them.
Due to the high risk of tuberculosis in patients
with inflammatory joint diseases treated with anti-
TNF drugs, the tuberculin skin test (TST) with two
units of RT23 and chest x-ray were performed be-
fore starting therapy. For further evaluation 14 pa-
tients (33.3%) were referred to specialized tubercu-
losis centers (Centros de Diagnóstico Pneumológi-
co, CDP) and eleven patients (26.2%) received latent
tuberculosis treatment. Tuberculin skin test was
performed in all patients prior to starting anti TNF
treatment but in two of them there was no registry
of the result. Six of the 27 patients with TST<5mm
repeated the test and in all of them the result was
less then 5mm. In none of them was prescribed
prophylactic therapeutic but 4 of the 24 patients
with initial TST<5mm and normal chest X-ray were
submitted to isoniazid treatment due to the presen-
ce of epidemiological risk factors for tuberculosis
(in 2 isoniazid 300mg/day during 6 months was
prescribed and in the other 2 it was taken during 9
months). In 5 of the 8 patients with TST 5-10mm
isoniazid (300mg/day during 6 months in 4 patients
and during 9 months in 1) was prescribed due to the
presence of prior immunosuppressive treatment.
All the 5 patients with TST>10mm received latent
tuberculosis treatment: 3 were treated with isonia-
zid 300mg/day during 9 months, 1 received isonia-
zid 300mg/day during 6 months and 1 isoniazid
and rifampicin during 3 months. 
At the time of the current evaluation, in a total
of 42 patients, 18 were under treatment with eta-
nercept (42.9%), 16 with infliximab (38.1%) and 8
with adalimumab (19%). Only 26.2% were on mo-
notherapy with anti-TNF drugs and the majority
(73.8%) was being treated with an associated con-
ventional DMARD. In 18 patients treated with eta-
nercept, only 5 (27.8%) were on monotherapy and
most (55.5%) were being treated concomitantly
with methotrexate (MTX). For the 16 patients 
being treated with infliximab only 37.5% were on
monotherapy and 57.3% have associated MTX or
other DMARDs. All of the adalimumab treated pa-
tients were receiving concomitant MTX (Table I).  
Fourteen patients (33.3%) had to switch their
TNF antagonist treatment and 3 of them made two
switches, so in total there were 17 switches. 58.8%
of the switches were due to adverse effects and
41.2% due to therapy failure (Table II). 
To evaluate the 81% of patients with predomi-
nant peripheral joint involvement the 68 joint
counts and the DAS28 score were applied. The ave-
rage initial (at the beginning of biologic therapy)
number of tender joints (68 joint count) was
16.3±10.4 and the final (at the moment of evalua-
tion) was 3±5.1 (p=0.00005). The swollen joint (68
joint count) count at the beginning of treatment
was 9.4±9.7 and at the final evaluation was 1.2±2.6
(p=0.0000659) (Figure 1). The initial DAS28 was
3.6±2.6 and the final was 3±1.6 (p=0.140) (Figure 2).
Table I. Biological therapy and DMARDs 
Monotherapy MTX SLZ MTX/PDN MTX/PDN/SLZ PDN TOTAL
Infliximab 37.5 12.5 6.25 31.25 12.5 0 100
Etanercept 27.8 44.4 5.6 11.1 0 11.1 100
Adalimumab 0 62.5 0 25 12.5 0 100
Number of DMARDs (percentages) currently in use in association with biological therapy (anti-TNF) on Psoriatic Arthritis patients 
MTX: Methotrexate; SLZ: Sulphasalazine; PDN: Prednisone
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For the 19% of PsA patients with spinal involve-
ment – “AS like patients” BASDAI and BASFI were
used. The average initial BASDAI was 4.3±2.9 and
the final was 3.4±1.9 (p=0,263). The average initial
BASFI was 4.7±1.6 and the final was 4.3±1.9
(p=0.386) (Figure 3 and 4).
Concerning the acute phase reactants, the ini-
tial ESR was 25.9±21.9 mm/1st hour and the final
was 19.1±21.5 mm/1st hour (p=0.084). The initial
CRP was 2.1±3.7 mg/dL and the final 0.9±1.8 mg/
/dL (p=0.04). 
To assess skin disease in PsA the PASI was used.
The mean initial PASI was 6.3±13.5 and the final
was 2.2±5.5 (p=0,056) (Figure 5). In 40.5% of pa-
tients there was a reduction of at least 50% of the
PASI value. 
Table II. Switch between biological therapies 
Current Number Reason for Switch
Previous therapy therapy of patients Adverse effects Therapeutic failure
Etanercept (8) Infliximab 6 Pancreatitis – 1 
Injection site reaction – 2 3
Adalimumab 2 Injection site reaction – 2 0
Infliximab (7) Etanercept 3 Injections site reaction – 1
Upper respiratory infection – 1 1
Adalimumab 4 Injection site reaction – 2
Transaminitis – 1 1
Adalimumab (2) Infliximab 1 0 1
Etanercept 1 0 1
Number and reason for switches (in absolute numbers) 
2
0
18
8
4
6
10
12
16
14
Initial Final
Tender joints
Swollen joints
p=0,00005
p=0,00007
N-68
Figure 1. Number of tender and swollen joints initial 
and final (at the moment of the last evaluation) of the 81%
of patients with peripheral involvement (mean follow-up –
37.8±27.8 months).
0
7
1
4
2
3
5
6
Initial Final
p=0,140
Figure 2. Value of DAS 28 (Disease Activity Score) initial
and final (at the moment of the last evaluation) of the 81%
of patients with peripheral involvement (mean follow-up –
37.8±27.8 months).
To assess physical function the self-reported
questionnaire HAQ was used. The initial HAQ was
1.5±1 and the final was 0.7±0.8 (p=0.0002). 
At the end of the evaluation period, 28.6 % of the
peripheral joints affected patients had a DAS28 su-
perior to 3.2, 12.5% of the axial involved patients
had a BASDAI superior to 40 and 60% improved
less than 50% in their skin condition. 
The only documented severe adverse reaction
was due to a case of pancreatitis, which was con-
sidered by the assisting physician to be unlikely re-
lated to the use of TNF antagonists. In 23.8% of the
mild adverse reactions, the drug had to be discon-
tinued definitely and switched to another TNF an-
tagonist, while in the remaining patients a tempo-
rary drug withhold proved to be enough. No tuber-
culosis case was registered. According to the expo-
sure time, 1.3 serious adverse reactions occurred
by 100 patient-year (Figure 6).
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Discussion
The results of this first report of the use of the Bio-
RePortAP in clinical practice confirm the efficacy
and safety of TNF antagonist treatment in PsA. In
fact, in a cohort of 42 patients, with a mean treat-
ment duration of 37.8±27.8 months (minimum ex-
posure to the drug of 9 months) in the patients
with peripheral joint disease there was a mean re-
duction of more than 80% in the swollen and ten-
der joint counts and in those with an axial invol-
vement there was a mean reduction in the BASDAI
score of 34%. On top of that, the mean PASI score
suffered a reduction of 64%. On the other hand, in
this group of patients there was a low rate of serio-
us adverse effects, although a relatively high num-
ber of mild adverse effects were reported. 
The impact on functional scores, such as BASFI
(mean reduction of 0.5) and HAQ (mean reduction
of 0.9), reflects the relatively long disease duration
that these patients had at the time of starting the-
se drugs. However, this disease duration (slightly
less than 8 years) is lower than the one that was ve-
rified in the previous RA (almost 12 years) and AS
(almost 14 years) Portuguese cohorts of patients
treated with biotechnology drugs17,18.
Fourteen patients (33.3%) had to switch from
one TNF antagonist to another one due to lack of
efficacy in 41.2% of the cases. Three of these pa-
tients had to switch again to a third anti TNF drug
also due to lack of efficacy. The remaining causes
for switching were adverse effects. Even with addi-
tional measures to ensure the effectiveness of treat-
0
8
1
2
5
3
4
6
7
Initial Final
p=0,263
Figure 3. Bath Ankylosing Spondylitis Disease Activity Index
initial and final (at the moment of the last evaluation) of
the 19% of patients with axial involvement (mean follow-up
– 37.8±27.8 months).
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p=0,386
Figure 4. Bath Ankylosing Spondylitis Functional Index initial
and final (at the moment of the last evaluation) of the 19%
of patients with axial involvement (mean follow-up –
37.8±27.8 months).
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Figure 5. Psoriatic Area and Severity Index (PASI) initial and 
final (at the moment of the last evaluation) in all the pa-
tients (mean follow-up - 37.8±27.8 months).
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Figure 6. Number of adverse reactions per 100 patient-
-years.
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ment such as switching and associating DMARDs
(73.8% of the patients) there were 28.6 % of the pe-
ripheral affected patients with a DAS28 superior to
3.2, 12.5% of the axial involved patients with a 
BASDAI superior to 40 and 60% improved less than
50% in their skin condition. Moreover, the impro-
vements observed in mean DAS28 and mean BAS-
DAI scores were not statistically significative. These
observations suggest that some of these patients
should be reassessed for treatment optimization
(classical DMARD readjustment, switch to another
TNF antagonist and review of the treatment opti-
ons for skin disease).
The dissociation between the reduction in the
68 joint count and the results of the DAS28 score
suggest that DAS28 is a weak discriminating as-
sessment toll for PsA.
Due to the high incidence of tuberculosis in the
general Portuguese population, particularly in in-
flammatory joints diseases treated with anti-TNF
drugs, strict recommendations for the diagnosis
and treatment of latent tuberculosis infection were
elaborated by the Portuguese Society of Rheuma-
tology22. Since 2002, specific guidelines for scree-
ning candidates to anti-TNF therapy for active and
latent TB have been followed. The first version of
these guidelines was published in September 2006
and placed on the General Directorate of Health In-
ternet website in December 200623. Before this
date, the threshold of TST positivity was higher
(TST>10mm) and that explains why 3 of the pa-
tients, who had TST between 5 and 10mm and star-
ted biological therapy before 2002 didn't receive la-
tent tuberculosis infection treatment. In the recent
Portuguese recommendations the TST is conside-
red positive if: ≥5mm in any patient who is about
to start anti-TNF treatment and is concomitantly
immunossuppressed (prednisolone in doses hig-
her than 10 mg/day and/or with immunosuppres-
sant drugs, such as MTX, cyclosporine, azathiopri-
ne, leflunomide or cyclophosphamide, regardless
of the dose); or ≥10 mm in patients who are not tak-
ing previous immunossuppressing drugs. Four of
the patients had a negative TST but were, also in
accordance to these guidelines, submitted to treat-
ment because they were immunossuppressed and
had epidemiologic risk factors for tuberculosis.
Fourteen of the patients were referred to Centro
Diagnóstico Pneumológico (CDP) or to a Pulmo-
nology Department, corresponding to the ones
that had started the treatment more recently, fol-
lowing the 2008 updated version of these guideli-
nes that recommend that all patients in evaluation
for TNF antagonist therapy should be referred to a
tuberculosis specialized centre. 
Regarding safety it is important to highlight that
several mild infectious adverse effects were detec-
ted. However, severe adverse effects were very rare.
The way the Day Care Unit of Rheumatology De-
partment of the Hospital de Santa Maria is organi-
zed favors the detection of all the complications
because patients are advised to seek medical sup-
port in the Day Care Unit whenever a complicati-
on occurs. On the other hand, this easy contact
combined with a low threshold for the diagnosis of
infections might contribute to the low rate of se-
vere adverse effects.
The results shown here elucidate the potential
applications of BioRePortAP as a tool for efficacy
and safety assessment of PsA patients treated with
biotechnological drugs. Moreover this informatics
tool can also act as a guarantee of good clinical
practice and a source of data for self assessment of
a Rheumatology department.
The characteristics of this first report of the Bio-
RePortAP, including only a population that was on
therapy at a certain date (September 2009), limits
the type of conclusions that can be achieved. Ho-
wever, at long term evaluations, BioRePortAP will
be able to inform precisely on drug survival, which
is the main limitation of the current assessment.
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